Expanding first-line therapy options for children with partial seizures

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Carbamazepine and phenytoin are established first-line treatments for pediatric partial seizures based on adult data and limited pediatric studies.
• New antiepileptic drugs (AEDs) efficacy in adults does not automatically translate to first-line status in children, necessitating specific pediatric evaluations.

Purpose of the Study:

• To establish criteria for evaluating new AEDs as first-line therapy for pediatric partial seizures.
• To assess the suitability of newer AEDs for first-line use in children with partial seizures based on proposed criteria.

Main Methods:

• Proposed three criteria: (a) efficacy in pediatric partial seizures via ≥2 randomized, double-blind controlled trials (≥1 monotherapy) in children <12 years old, (b) favorable monotherapy safety profile with no severe idiosyncratic reactions, and (c) ease of use across pediatric age ranges.
• Evaluated oxcarbazepine (OXC), topiramate (TPM), and gabapentin (GBP) against these criteria.

Main Results:

• Oxcarbazepine (OXC) and topiramate (TPM) meet the criteria for consideration as first-line therapy for pediatric partial seizures.
• OXC demonstrated efficacy in monotherapy and adjunctive pediatric trials with good tolerability and rapid titration.
• TPM showed efficacy and tolerability in pediatric partial seizures but requires slow titration; GBP may be considered if monotherapy trial data are confirmed.

Conclusions:

• Oxcarbazepine and topiramate are suitable candidates for first-line therapy in pediatric partial seizures based on rigorous evaluation criteria.
• Further data are needed for lamotrigine, tiagabine, felbamate, levetiracetam, and zonisamide before they can be considered first-line options.
• Establishing specific pediatric evidence is crucial for advancing AEDs beyond established treatments for childhood epilepsy.